241 related articles for article (PubMed ID: 33251992)
1. Annual health care resource utilization and cost among type 2 diabetes patients with newly recognized chronic kidney disease within a large U.S. administrative claims database.
Folkerts K; Petruski-Ivleva N; Kelly A; Fried L; Blankenburg M; Gay A; Kovesdy CP
J Manag Care Spec Pharm; 2020 Dec; 26(12):1506-1516. PubMed ID: 33251992
[No Abstract] [Full Text] [Related]
2. Cardiovascular and Renal Outcomes in Patients with Type-2 Diabetes and Chronic Kidney Disease Identified in a United States Administrative Claims Database: A Population Cohort Study.
Folkerts K; Kelly AMB; Petruski-Ivleva N; Fried L; Blankenburg M; Gay A; Velentgas P; Kovesdy CP
Nephron; 2021; 145(4):342-352. PubMed ID: 33789294
[TBL] [Abstract][Full Text] [Related]
3. Actionable Real-World Evidence to Improve Health Outcomes and Reduce Medical Spending Among Risk-Stratified Patients with Diabetes.
Garry EM; Schneeweiss S; Eapen S; Petruski-Ivleva N; Cheever E; Murk W; Rajan A; Rassen JA; Gambino D; Jang H; Rubin E; Jan S
J Manag Care Spec Pharm; 2019 Dec; 25(12):1442-1452. PubMed ID: 31778623
[TBL] [Abstract][Full Text] [Related]
4. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
Wallace AE; Kaila S; Bayer V; Shaikh A; Shinde MU; Willey VJ; Napier MB; Singer JR
J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096
[TBL] [Abstract][Full Text] [Related]
5. Estimation of Annual Health Care Costs for Adults with Type 1 Diabetes in the United States.
Joish VN; Zhou FL; Preblick R; Lin D; Deshpande M; Verma S; Davies MJ; Paranjape S; Pettus J
J Manag Care Spec Pharm; 2020 Mar; 26(3):311-318. PubMed ID: 32105172
[TBL] [Abstract][Full Text] [Related]
6. Association of dyskalemias with short-term health care utilization in patients with advanced CKD.
Dashputre AA; Gatwood J; Sumida K; Thomas F; Akbilgic O; Potukuchi PK; Obi Y; Molnar MZ; Streja E; Kalantar-Zadeh K; Kovesdy CP
J Manag Care Spec Pharm; 2021 Oct; 27(10):1403-1415. PubMed ID: 34595956
[No Abstract] [Full Text] [Related]
7. The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study.
Campbell A; Cong Z; Agodoa I; Song X; Martinez DJ; Black D; Lew CR; Varker H; Chan C; Lanzkron S
J Manag Care Spec Pharm; 2020 Sep; 26(9):1121-1129. PubMed ID: 32597290
[TBL] [Abstract][Full Text] [Related]
8. Descriptive study of the economic burden among patients with type 2 diabetes mellitus, chronic kidney disease, and chronic kidney disease and type 2 diabetes mellitus in a large US commercially insured population.
Chung H; Crowe CL; Kong SX; Singh R; Farej R; Elliott J; Williamson T; Willey VJ
J Manag Care Spec Pharm; 2023 Jan; 29(1):80-89. PubMed ID: 36580126
[No Abstract] [Full Text] [Related]
9. Health care resource utilization among patients with T2D and cardiovascular-, heart failure-, or renal-related hospitalizations.
Annavarapu S; Ghosh S; Li Y; Moretz C; Shetty S; Prewitt T
Am J Manag Care; 2020 Jun; 26(6):e166-e171. PubMed ID: 32549065
[TBL] [Abstract][Full Text] [Related]
10. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
[TBL] [Abstract][Full Text] [Related]
11. Patients with Idiopathic Membranous Nephropathy: A Real-World Clinical and Economic Analysis of U.S. Claims Data.
Nazareth TA; Kariburyo F; Kirkemo A; Xie L; Pavlova-Wolf A; Bartels-Peculis L; Vaidya N; Sim JJ
J Manag Care Spec Pharm; 2019 Sep; 25(9):1011-1020. PubMed ID: 31283419
[TBL] [Abstract][Full Text] [Related]
12. The economic burden of progressive chronic kidney disease among patients with type 2 diabetes.
Vupputuri S; Kimes TM; Calloway MO; Christian JB; Bruhn D; Martin AA; Nichols GA
J Diabetes Complications; 2014; 28(1):10-6. PubMed ID: 24211091
[TBL] [Abstract][Full Text] [Related]
13. The association between the severity of chronic kidney disease and medical costs among patients with type 2 diabetes.
Lage MJ; Boye KS; Bae JP; Wu J; Mody R; Botros FT
J Med Econ; 2019 May; 22(5):447-454. PubMed ID: 30736708
[TBL] [Abstract][Full Text] [Related]
14. Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency.
Latremouille-Viau D; Guerin A; Gagnon-Sanschagrin P; Dea K; Cohen BG; Joseph GJ
J Manag Care Spec Pharm; 2017 Feb; 23(2):214-224. PubMed ID: 28125373
[TBL] [Abstract][Full Text] [Related]
15. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
[TBL] [Abstract][Full Text] [Related]
16. A Real-World Claims Analysis of Costs and Patterns of Care in Treated Patients with Glioblastoma Multiforme in the United States.
Norden AD; Korytowsky B; You M; Kim Le T; Dastani H; Bobiak S; Singh P
J Manag Care Spec Pharm; 2019 Apr; 25(4):428-436. PubMed ID: 30917077
[TBL] [Abstract][Full Text] [Related]
17. Economic burden of major bleeding events in commercially insured patients with von Willebrand disease based on claims data from the United States.
Lu M; Oladapo A; Wu Y; Farahbakhshian S; Ewenstein B
J Manag Care Spec Pharm; 2021 Feb; 27(2):175-185. PubMed ID: 33307935
[No Abstract] [Full Text] [Related]
18. The Economic Burden of Comorbid Obstructive Sleep Apnea Among Patients with Chronic Obstructive Pulmonary Disease.
Hong YD; Onukwugha E; Slejko JF
J Manag Care Spec Pharm; 2020 Oct; 26(10):1353-1362. PubMed ID: 32996389
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcomes and Healthcare Resource Utilization in a Real-World Population Reflecting the DAPA-CKD Trial Participants.
Olufade T; Lamerato L; Sánchez JJG; Jiang L; Huang J; Nolan S; Rangaswami J
Adv Ther; 2021 Feb; 38(2):1352-1363. PubMed ID: 33474707
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Economic Impact of Hyperkalemia in Patients with Chronic Kidney Disease and Heart Failure.
Polson M; Lord TC; Kangethe A; Speicher L; Farnum C; Brenner M; Oestreicher N; Alvarez P
J Manag Care Spec Pharm; 2017 Apr; 23(4-a Suppl):S2-S9. PubMed ID: 28436256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
